These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 5015790)

  • 21. The influence of D-glucose and p-aminosalicylic acid on the metabolism of isoniazid.
    Peters JH; Gill M; Hayes VE
    Arch Int Pharmacodyn Ther; 1966 Feb; 159(2):340-52. PubMed ID: 5916739
    [No Abstract]   [Full Text] [Related]  

  • 22. [Side effects of antibacterial drugs in the clinical course of pulmonary tuberculosis].
    Czkwianianc M; Markiewicz I
    Przegl Lek; 1969 Jun; 25(6):479-81. PubMed ID: 5805095
    [No Abstract]   [Full Text] [Related]  

  • 23. [Modification of side effects from tuberculostatic agents by metoclopramide].
    Pollack KP
    Ther Ggw; 1967 Dec; 106(12):1606 passim. PubMed ID: 5622114
    [No Abstract]   [Full Text] [Related]  

  • 24. [Comparative study (tolerance and effectiveness) of classic antituberculous therapy (P.A.S.-streptomycin-isoniazid) and a new combination (prothionamide-streptomycin-isoniazid)].
    Charpin J; Taranger J; Boutin C; Girbal JP
    Mars Med; 1969; 106(11):895-7. PubMed ID: 5407168
    [No Abstract]   [Full Text] [Related]  

  • 25. [Effect of sodium para-aminosalicylate on the concentration of isoniazid (tubazid) in the blood of patients with tuberculosis].
    Kozulitsina TI; Korotaev GA
    Ter Arkh; 1969; 41(10):94-7. PubMed ID: 5359356
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparative study of biweekly streptomycin and isoniazid with daily P.A.S. and isoniazid regimens in the treatment of pulmonary tuberculosis.
    Mathur JB; Bahadur P; Agnihotri CB
    J Indian Med Assoc; 1967 Aug; 49(4):162-5. PubMed ID: 5594009
    [No Abstract]   [Full Text] [Related]  

  • 27. [Value of the immunological tests in the diagnosis of adverse effects of tuberculostatic therapy].
    Averbakh MM; Keleberda KIa; Gergert VIa; Mingazitinova DM
    Probl Tuberk; 1980 Mar; (3):27-30. PubMed ID: 6994091
    [No Abstract]   [Full Text] [Related]  

  • 28. [Intravenous injection of isoniazid and PAS twice weekly to outpatients with tuberculosis in rural areas].
    Ursov IG; Volokitin FN; Borovinskaia TA
    Probl Tuberk; 1983 Nov; (11):42-5. PubMed ID: 6675002
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical effect of cycloserine on cavity-size, frequency of improvement with remarks on control of side effects.
    Trendelenburg F
    Scand J Respir Dis Suppl; 1970; 71():168-71. PubMed ID: 5271968
    [No Abstract]   [Full Text] [Related]  

  • 30. [Comparison of efficiency of large and small doses of isoniazid in combined treatment in pulmonary tuberculosis].
    Mysakowska H; Grodzki S; Przemyska B; Szarewicz W; Srednicka D
    Pol Tyg Lek; 1965 Apr; 20(16):562-4. PubMed ID: 5834844
    [No Abstract]   [Full Text] [Related]  

  • 31. [Our region's possibilities in the ambulatory treatment of pulmonary tuberculosis with the biweekly administration of a perfused triple combination of isoniazid, streptomycin and PAS].
    Burghard G; Petitjean R; Scherrer B; Schranz J
    Rev Tuberc Pneumol (Paris); 1970; 34(5):662-3. PubMed ID: 5496786
    [No Abstract]   [Full Text] [Related]  

  • 32. The role of the metabolism of p-aminosalicylic acid (PAS) in the treatment of tuberculosis. Interaction with the metabolism of isonicotinic acid hydrazide (INH) and the synthesis of cholesterol.
    Lehmann J
    Scand J Respir Dis; 1969; 50(3):169-85. PubMed ID: 5195904
    [No Abstract]   [Full Text] [Related]  

  • 33. [Pharmacogenetic and interaction-model with some usual antitubercular agents].
    Hanngren A; Boman G; Borgå O; Malmborg AS; Sjöqvist F
    Nord Med; 1970 Sep; 84(38):1204. PubMed ID: 5469274
    [No Abstract]   [Full Text] [Related]  

  • 34. Lupus vulgaris and Hodgkin's disease.
    Schein PS; Vickers HR
    Arch Dermatol; 1972 Feb; 105(2):244-6. PubMed ID: 5060868
    [No Abstract]   [Full Text] [Related]  

  • 35. [Criteria and methods for determination of the HINA preparations inactivation].
    Smirnov GA
    Probl Tuberk; 1972; 50(4):54-61. PubMed ID: 5063046
    [No Abstract]   [Full Text] [Related]  

  • 36. [Anaphylactic shock caused by Fintozid].
    Földeş I; Norbert G
    Ftiziologia; 1971; 20(4):429-31. PubMed ID: 5162280
    [No Abstract]   [Full Text] [Related]  

  • 37. [Evaluation of alternative regimen of SM-INH-PAS and KM-TH-CS at three months interval in initial treatment of far advanced pulmonary tuberculosis. A report of the 12th series controlled trial of chemotherapy].
    Kekkaku; 1972 Jun; 47(6):151-8. PubMed ID: 5081204
    [No Abstract]   [Full Text] [Related]  

  • 38. Results of one-year chemotherapy with isoniazid (INH), streptomycin (SM) and ethionamide (ETA) in previously untreated patients with cavernous pulmonary tuberculosis.
    Zajaczkowska J; Krychniak W; Krakówka P; Buraczewska M
    Pol Med J; 1966; 5(2):339-44. PubMed ID: 5915720
    [No Abstract]   [Full Text] [Related]  

  • 39. [The use of isonicotinylhydrazide paraaminosalicylate in treatment of the primary infection in children].
    Fouquet J; Teyssier L
    Cah Coll Med Hop Paris; 1965 Nov; 6(10):713-6. PubMed ID: 5295164
    [No Abstract]   [Full Text] [Related]  

  • 40. [Diagnostic and therapeutic problems in osteoarticular tuberculosis].
    Wośko I
    Pol Tyg Lek; 1968 May; 23(19):693-5. PubMed ID: 5670207
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.